C71T
CANCELLED SECTION 71
06/03/2026
Voltar para busca
Dado oficial do USPTO
GLYCOM
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
50
Atualização mais recente
31/03/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5
Data de depósito
26/09/2012
Data de registro
03/12/2013
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
06/03/2026
Última transação
31/03/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
709
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
Hørsholm, DK
Examinador
DE JONGE, KATHLEEN
Unidade examinadora
L70
Localização atual
GENERIC WEB UPDATE
Titulares e representantes
Titulares
GLYCOM A/S
Representantes
Stephanie L. Crigler Dinsmore & Shohl LLP
Classificação técnica
Classes Nice
Classe 1Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Human milk oligosaccharide (HMO) preparations for use in industry and as raw material in the manufacture of other goods and other than for medical use; human milk oligosaccharide (HMO) additives for use in the manufacture of pharmaceuticalsnutraceuticalsinfant formulafoodstuffs and animal foods; human milk oligosaccharide compoundschemical and biological derivatives of human milk oligosaccharide compounds and chemical and biological precursors of human milk oligosaccharide compounds for the food industry; human milk oligosaccharide compoundschemical and biological derivatives of human milk oligosaccharide compounds and chemical and biological precursors of human milk oligosaccharide compounds for scientific use other than for medical or veterinary use; human milk oligosaccharide compoundschemical and biological derivatives of human milk oligosaccharide compounds and chemical and biological precursors of human milk oligosaccharide compounds for industrial use; human milk oligosaccharide compoundschemical and biological derivatives of human milk oligosaccharide compounds and chemical and biological precursors of human milk oligosaccharide compounds for use in the manufacture of pharmaceuticalsnutraceuticalsinfant formulafoodstuffs and animal foods; chemicals for use as a supplement in the preparation of dietary supplements and infant formula
Classe 5
Dietetic food and substanceshuman milk oligosaccharide adapted for medical or veterinary usefood for babies and infant formula; dietary supplements for humans and animals; medicated food additives in the nature of dietary supplements containing human milk oligosaccharide for humans and for animals; medicated preparations for use as additives for food for human or animal consumptionhuman milk oligosaccharide for medical or veterinary purposesvitamin preparations for use as a supplement for dietary supplements and infant formula; food supplements for dietetic use; dietary supplements for medical use; medicated supplements for foodstuffs for humansincluding for infantsfor animals; mineral food supplements; colostrum supplements; dietary supplemental drinks and nutritionally fortified beverages; dietary supplements for infants; human milk oligosaccharide dietary supplements; human milk oligosaccharide compounds for medical purposes; human milk oligosaccharide additives being dietary and nutritional supplements for use as supplements in connection with pharmaceuticalsnutraceuticals and infant formula; human milk oligosaccharide additives for use as a dietary or nutritional supplement; human milk oligosaccharide compounds and chemical and biological derivatives of human milk oligosaccharide compounds for medical use
Publicações
Histórico de despachos e eventos da marca no USPTO.
50 publicações encontradas
NREP
NEW REPRESENTATIVE AT IB RECEIVED
15/11/2024
REM4
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
03/12/2022
RNWL
INTERNATIONAL REGISTRATION RENEWED
14/10/2022
NREP
NEW REPRESENTATIVE AT IB RECEIVED
23/04/2021
NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
05/02/2020
71AG
REGISTERED-SEC.71 ACCEPTED
05/02/2020
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
23/01/2020
NREP
NEW REPRESENTATIVE AT IB RECEIVED
16/01/2020
ES71
TEAS SECTION 71 RECEIVED
02/12/2019
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
03/12/2018
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
08/01/2018
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
08/01/2018
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
24/08/2017
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
15/09/2016
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
15/09/2016
NREP
NEW REPRESENTATIVE AT IB RECEIVED
21/07/2016
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
03/04/2014
FICS
FINAL DISPOSITION NOTICE SENT TO IB
17/03/2014
FIMP
FINAL DISPOSITION PROCESSED
17/03/2014
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
03/03/2014
R.PR
REGISTERED-PRINCIPAL REGISTER
03/12/2013
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
17/09/2013
PUBO
PUBLISHED FOR OPPOSITION
17/09/2013
GPNX
NOTIFICATION PROCESSED BY IB
16/09/2013
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
28/08/2013
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
28/08/2013
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
28/08/2013
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
10/08/2013
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/08/2013
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/08/2013
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/08/2013
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
05/08/2013
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
19/07/2013
GNFR
FINAL REFUSAL E-MAILED
19/07/2013
CNFR
FINAL REFUSAL WRITTEN
19/07/2013
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
19/07/2013
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
19/07/2013
ALIE
ASSIGNED TO LIE
11/07/2013
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/07/2013
RFNT
REFUSAL PROCESSED BY IB
03/06/2013
MAFR
APPLICATION FILING RECEIPT MAILED
18/05/2013
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
15/05/2013
RFRR
REFUSAL PROCESSED BY MPU
15/05/2013
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
15/05/2013
CNRT
NON-FINAL ACTION WRITTEN
14/05/2013
DOCK
ASSIGNED TO EXAMINER
14/05/2013
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
14/05/2013
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
13/05/2013
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
09/05/2013
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace GLYCOM ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.